OIG Finds Medicare Overpaying for Continuous Glucose Monitors; Recommends Payment Cuts
OIG report identifies Medicare overpayments for continuous glucose monitors and urges CMS to reduce payment rates, highlighting potential savings.
Georgia 2026 Laws Update: Insurance Affordability, Tax Cuts, and Regulatory Changes
Explore Georgia's key 2026 legislative changes impacting insurance affordability, state income tax reductions, consumer protections, teledentistry, property regulations, and more.
CMS Proposes Key Changes to Medicare Advantage Star Ratings and Regulatory Streamlining for 2027
CMS releases 2027 Medicare Advantage and Part D proposed rule focusing on Star Ratings adjustments, regulatory burden reduction, and program spending projections.
CMS Proposes Major Medicare Advantage and Part D Program Updates for 2027
CMS proposes significant updates to Medicare Advantage and Part D programs for 2027, including Star Ratings revisions and increased quality bonuses, impacting Medicare spending and compliance.
Humana Appeals CMS Over Medicare Advantage Star Ratings Dispute
Humana appeals CMS over Medicare Advantage star ratings, contesting calculation methods and evaluation processes affecting bonuses and plan ratings.
Hospitals Sue HHS Over 340B Pilot Program Changes
Hospitals challenge HHS's 340B pilot shifting drug discounts to a rebate system, citing financial risks and regulatory concerns.
CMS to Revise Medicare Hospital Payment Weights Using Market-Based Data for FY2029
CMS plans to change Medicare hospital payment weights methodology using Medicare Advantage data starting FY2029, impacting hospital reimbursement and clinical documentation.
Medicare Drug Price Negotiations Expand to 15 More Medications in 2027
CMS expands Medicare drug price negotiations to 15 more medications starting in 2027, including popular diabetes and weight loss treatments, aiming to reduce prescription costs and save Medicare billions.
CMS Launches Voluntary Medicaid MFN Drug Pricing Model; Trump-Era Manufacturer Agreements Expand
CMS unveils the GENERous Medicaid payment model introducing MFN drug pricing, alongside expanded Trump administration drug pricing agreements and key regulatory updates for 2026.
FDA Approves Leucovorin for Autism Amid Investment and Regulatory Clarifications
FDA approves prescription leucovorin for autism treatment; HHS addresses investment and regulatory concerns involving CMS administrator Dr. Mehmet Oz amid public discourse.